

**REMARKS**

The examiner considers the claims to be drawn to eight inventions or groups of inventions (I-VIII) which are not so linked as to form a single general inventive concept under PCT Rule 13.1 and requires restriction to a single invention or group.

Applicants elect with traverse Group VII, presently comprising claims 86, 91-93 and newly added claim 102. Traversal insofar as claims 87-90 (it is noted that claim 90 is not included in any specific group) are concerned is due to there being no basis for isolating these claims (designated as part of Group VI) from the other groups drawn also to a method for treating a disease. Paragraph [0130] discloses in the specification (US2009 0217400) that "Asymmetric recombination of sites using a combination of recombinases may be utilized for treating a variety of diseases. For example, the working of the present invention may be utilized for excision of HIV provirus for the genome of infected cells. It is requested that claims 87-90 be rejoined with the elected Group VII.

With regard to the election of species requirement for Group VII, applicants elect the specie of microparticles, as recited in claim 86 without traverse.

It is understood that, upon allowance of a generic claim, applicants will be entitled to consideration of claims to

Appln. No. 10/590,897

Amd. dated January 13, 2011

Reply to Office Action of October 13, 2010

additional species which depend from or otherwise require all the limitations of an allowable generic claim.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By /ACY/  
Allen C. Yun  
Registration No. 37,971

ACY:pp

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

G:\BN\W\Webb\Carmil\pto\2011-01-13Amendment.doc